Arsanis nabs $45.5 mln Series D


Waltham, Massachusetts-based Arsanis Inc, a developer of targeted monoclonal antibodies for treating serious infectious diseases, has raised $45.5 million in Series D financing. Bill & Melinda Gates Foundation led the round with participation from other investors that included GV, Alexandria Venture Investments, OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures and the Anna Maria and Stephen Kellen Foundation.

Source: Press Release

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!